The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.

The disclosure relates to a mixture of bacteria belonging to at least six or seven different and specific bacterial species preferably for use in preventing or treating gastro-intestinal disorders. Preferably, the mixture of bacteria is grown together in a fermenter prior to administering the mixture to a subject in order to prevent or treat the disorder.

Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.

The present invention relates to a composition for growing the population of microorganisms in a gut of monogastric animals, and methods for growing the same. The present invention also relates to a method for enhancing an average daily gain of monogastric animals.

The present invention relates to a composition for growing the population of microorganisms in a gut of monogastric animals, and methods for growing the same. The present invention also relates to a method for enhancing an average daily gain of monogastric animals.

The present invention provides preparation of a semicarbazide-sensitive amine oxidase inhibitor and use thereof. In particular, disclosed in the present invention are a compound as represented by formula I, or a stereoisomer or a racemate or a pharmaceutically acceptable salt of the compound. Also disclosed in the present invention is that the compound can inhibit semicarbazide-sensitive amine oxidase.

##STR00001##

A method is described for delivering a single domain antibody or a therapeutic molecule from an apical surface of a polymeric immunoglobulin receptor (pIgR)-expressing cell to a basolateral surface of the pIgR-expressing cell comprising contacting the pIgR-expressing cell with the single domain antibody or the therapeutic molecule, wherein the single domain antibody binds to pIgR, and the therapeutic molecule comprises an agent and the single domain antibody. A method is also described for transporting such a therapeutic molecule to systemic circulation or lamina propria or gastrointestinal tract of a subject comprising administering the therapeutic molecule to the subject via oral delivery, buccal delivery, nasal delivery or inhalation delivery.

Provided are dietary supplement composition comprising one or both of L-theanine and a trace mineral complex, optionally in combination with bioactive peptides, in an amount or amounts individually or in combination effective to promote gut health. Further optional components include a fiber oligosaccharide prebiotic, a polyphenol prebiotic, and a polynucleotide or blend. Examples of benefits include one or more of: —an increase in the amount of total short-chain fatty acid production or of at least one of propionate, acetate and butyrate; —an increase the expression or level of at least one tight junction protein (for example, claudin-1, claudin-3, claudin-4, occludin, or a zona occludens protein) or mucin-3 or decrease the expression or level of claudin-2; —an increase in transepithelial electrical resistance; —an increase in the abundance or diversity of a member or phylum of the intestinal bacterial community of the Intestinal lumen or mucus area (for example, Firmicutes, Bacteroidetes, Lactobacilli, Bifidobacteria, F. prausnitzii, or A. muciniphila); —an increase in the expression or level of at least one intestinal surface area marker protein (for example, villin, myosin, cadherin or sucrase-isomaltase). Methods for using such supplements are also disclosed.

Provided are dietary supplement composition comprising one or both of L-theanine and a trace mineral complex, optionally in combination with bioactive peptides, in an amount or amounts individually or in combination effective to promote gut health. Further optional components include a fiber oligosaccharide prebiotic, a polyphenol prebiotic, and a polynucleotide or blend. Examples of benefits include one or more of: —an increase in the amount of total short-chain fatty acid production or of at least one of propionate, acetate and butyrate; —an increase the expression or level of at least one tight junction protein (for example, claudin-1, claudin-3, claudin-4, occludin, or a zona occludens protein) or mucin-3 or decrease the expression or level of claudin-2; —an increase in transepithelial electrical resistance; —an increase in the abundance or diversity of a member or phylum of the intestinal bacterial community of the Intestinal lumen or mucus area (for example, Firmicutes, Bacteroidetes, Lactobacilli, Bifidobacteria, F. prausnitzii, or A. muciniphila); —an increase in the expression or level of at least one intestinal surface area marker protein (for example, villin, myosin, cadherin or sucrase-isomaltase). Methods for using such supplements are also disclosed.

New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.